AngioDynamics introduces DuraMax chronic dialysis catheter in the U.S.

NewsGuard 100/100 Score

AngioDynamics (NASDAQ:ANGO) announced today the U.S. launch and initial shipments of the next generation DuraMax® stepped-tip chronic dialysis catheter and the DuraMaxVP (VascPak™) kit.

The DuraMax catheter provides optimal ease of insertion and high performance blood flow rates. It features a proprietary guidewire lumen designed to significantly improve catheter placement by securely fixing the guidewire in the center of the leading edge of the catheter at the insertion site.

"Approximately 30-50% of chronic dialysis catheters are placed over a guidewire, and DuraMax offers a significant improvement in ease of catheter placement," said Shawn McCarthy, Senior Vice President and General Manager for AngioDynamics. "The DuraMax chronic dialysis catheter employs AngioDynamics' highly innovative and proprietary Curved Tip™ Catheter Technology, which is designed to improve patient outcomes by providing higher blood flow over a longer timeframe at lower recirculation rates, even if the catheter becomes positioned against a vessel wall."

The new DuraMaxVP (VascPak) product offers a streamlined component kit designed to appeal to vascular access centers and open this new segment for AngioDynamics. Up to 45% of all chronic dialysis catheter placements - more than 180,000 placements in 2011 - are performed in these outpatient centers.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Vaccines targeting chronic diseases show promise in combatting age-related conditions